share_log

Alzamend Neuro | 10-K: FY2024 Annual Report

Alzamend Neuro | 10-K: FY2024 Annual Report

Alzamend Neuro | 10-K：2024財年年報
美股SEC公告 ·  2024/07/31 10:20

Moomoo AI 已提取核心訊息

Alzamend Neuro reported a net loss of $9.9 million for fiscal year 2024, compared to $14.9 million in FY2023. Operating expenses decreased to $9.9 million from $14.9 million, with research and development costs at $6.5 million and general and administrative expenses at $3.5 million. The company ended the year with $376,000 in cash.The company made significant progress in its clinical programs during FY2024. For AL001, Alzamend successfully identified a maximum tolerated dose in Phase IIA trials and received FDA "study may proceed" letters for additional indications including bipolar disorder, major depressive disorder, and PTSD. The company also initiated a Phase I/IIA clinical trial for ALZN002 to treat mild to moderate dementia of Alzheimer's type.To strengthen its financial position, Alzamend secured new funding through Series B Preferred Stock sales to Ault Lending totaling $2.1 million and raised $1.3 million through an at-the-market offering. Post fiscal year-end, the company entered into agreements with Orchid Finance for up to $25 million in Series A Preferred Stock financing to advance its clinical programs.
Alzamend Neuro reported a net loss of $9.9 million for fiscal year 2024, compared to $14.9 million in FY2023. Operating expenses decreased to $9.9 million from $14.9 million, with research and development costs at $6.5 million and general and administrative expenses at $3.5 million. The company ended the year with $376,000 in cash.The company made significant progress in its clinical programs during FY2024. For AL001, Alzamend successfully identified a maximum tolerated dose in Phase IIA trials and received FDA "study may proceed" letters for additional indications including bipolar disorder, major depressive disorder, and PTSD. The company also initiated a Phase I/IIA clinical trial for ALZN002 to treat mild to moderate dementia of Alzheimer's type.To strengthen its financial position, Alzamend secured new funding through Series B Preferred Stock sales to Ault Lending totaling $2.1 million and raised $1.3 million through an at-the-market offering. Post fiscal year-end, the company entered into agreements with Orchid Finance for up to $25 million in Series A Preferred Stock financing to advance its clinical programs.
Alzamend Neuro報告2024財政年度淨虧損990萬美元，相較於2023財政年度的1490萬美元。營業費用從1490萬美元減少到990萬美元，研究與開發費用爲650萬美元，管理費用爲350萬美元。公司年末現金餘額爲376,000美元。在2024財政年度，公司的臨牀項目取得了重大進展。在AL001方面，Alzamend在IIA階段試驗中成功確定了最大耐受劑量，並收到了FDA的「研究可以繼續」信件，涉及雙相障礙、重度抑鬱障礙和創傷後應激障礙的額外適應症。公司還啓動了針對老年癡呆類型輕度至中度癡呆症的ALZN002 I/IIA期臨牀試驗。爲了增強財務狀況，Alzamend通過向Ault Lending銷售210萬美元的B系列優先股獲得了新資金，並通過市場掛牌募資130萬美元。在財政年度結束後，公司與蘭花協議簽署了高達2500萬美元的A系列優先股融資協議，以推進其臨牀項目。
Alzamend Neuro報告2024財政年度淨虧損990萬美元，相較於2023財政年度的1490萬美元。營業費用從1490萬美元減少到990萬美元，研究與開發費用爲650萬美元，管理費用爲350萬美元。公司年末現金餘額爲376,000美元。在2024財政年度，公司的臨牀項目取得了重大進展。在AL001方面，Alzamend在IIA階段試驗中成功確定了最大耐受劑量，並收到了FDA的「研究可以繼續」信件，涉及雙相障礙、重度抑鬱障礙和創傷後應激障礙的額外適應症。公司還啓動了針對老年癡呆類型輕度至中度癡呆症的ALZN002 I/IIA期臨牀試驗。爲了增強財務狀況，Alzamend通過向Ault Lending銷售210萬美元的B系列優先股獲得了新資金，並通過市場掛牌募資130萬美元。在財政年度結束後，公司與蘭花協議簽署了高達2500萬美元的A系列優先股融資協議，以推進其臨牀項目。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

獨立文件7  查看翻譯

獨立文件8  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Syros Pharmaceuticals
    SYRS
    -- 0.2299
    2seventy bio
    TSVT
    -- 4.930
    Dogwood Therapeutics
    DWTX
    -- 10.632
    Plus Therapeutics
    PSTV
    -- 1.5001
    Aprea Therapeutics
    APRE
    -- 2.580
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    特斯拉績後巨震，後市你怎麽看？
    特斯拉2024年Q4營收257.1億美元，同比增長2%，不及預期。Cybercab計劃2026年投產，預計車輛業務將於2025年恢復增長。面對特朗普回歸，特斯拉股價能否在2025年繼續攀升？
    TSLA收益預覽：猜測開盤價贏取獎勵！